1. Topoisomerase-IIα expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel
   Virginie Durbecq et al, 2004, Molecular Cancer Therapeutics CrossRef
2. Predictive and Prognostic Significance of the State of Gene TOP2A as a Marker of Anthracyclines Sensitivity in Patients with Breast Cancer
   М.А. Бармотько, 2021, Евразийский онкологический журнал CrossRef
3. Retrospective Analysis of Topoisomerase IIa Amplifications and Deletions As Predictive Markers in Primary Breast Cancer Patients Randomly Assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative Group
   Ann S. Knoop et al, 2005, Journal of Clinical Oncology CrossRef
4. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer
   Hideaki Tokiniwa et al, 2012, Breast Cancer CrossRef
5. Low-Level TOP2A Amplification in Prostate Cancer Is Associated with HER2 Duplication, Androgen Resistance, and Decreased Survival
   Amanda J. Murphy et al, 2007, Cancer Research CrossRef
6. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
   Antonio C. Wolff et al, 2007, Journal of Clinical Oncology CrossRef
7. Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy Trial
   John M.S. Bartlett et al, 2008, Journal of Clinical Oncology CrossRef
8. Topoisomerase IIα Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in HER-2/neu–Amplified Breast Cancer: Scandinavian Breast Group Trial 9401
   Minna Tanner et al, 2006, Journal of Clinical Oncology CrossRef